BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30987915)

  • 1. Throwing it in reverse: An update on reversal of oral factor Xa inhibitors.
    Gilbert BW; Reeder JA; Alkhalifah MA; Moran DA; Corvino MA
    Am J Emerg Med; 2019 Oct; 37(10):1978-1980. PubMed ID: 30987915
    [No Abstract]   [Full Text] [Related]  

  • 2. [Andexanet alfa: the best antidote for factor Xa inhibitors?].
    Klok FA; Huisman MV
    Ned Tijdschr Geneeskd; 2019 Jun; 163():. PubMed ID: 31283119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
    Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
    Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors.
    Nafee T; Aslam A; Chi G; Pahlavani S; Nimri D; Kuchkuntla AR; Talib U; Michalak N; Daaboul Y; Korjian S; Gallo A; Gibson CM
    Expert Rev Cardiovasc Ther; 2017 Apr; 15(4):237-245. PubMed ID: 28282497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.
    Milling TJ; Kaatz S
    Am J Med; 2016 Nov; 129(11S):S80-S88. PubMed ID: 27575436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical and clinical data for factor Xa and "universal" reversal agents.
    Milling TJ; Kaatz S
    Am J Emerg Med; 2016 Nov; 34(11S):39-45. PubMed ID: 27697443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
    Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
    N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants.
    Ansell JE
    J Thromb Thrombolysis; 2016 Feb; 41(2):248-52. PubMed ID: 26449414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Andexanet alfa or prothrombin complex concentrate for acute reversal of oral factor Xa inhibitors: monitoring of antidote effects.
    Tanaka KA; Levy JH
    Br J Anaesth; 2024 Feb; 132(2):215-217. PubMed ID: 38071150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When and How to Use Reversal Agents for Direct Oral Anticoagulants?
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R
    Curr Cardiol Rep; 2023 May; 25(5):371-380. PubMed ID: 36976497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidotes for reversal of direct oral anticoagulants.
    Dobesh PP; Bhatt SH; Trujillo TC; Glaubius K
    Pharmacol Ther; 2019 Dec; 204():107405. PubMed ID: 31521696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Andexanet alfa-The first 150 days.
    Culbreth SE; Rimsans J; Sylvester K; Pallin DJ; Connors JM
    Am J Hematol; 2019 Jan; 94(1):E21-E24. PubMed ID: 30358896
    [No Abstract]   [Full Text] [Related]  

  • 13. Reversal agents for non-vitamin K antagonist oral anticoagulants.
    Levy JH; Douketis J; Weitz JI
    Nat Rev Cardiol; 2018 May; 15(5):273-281. PubMed ID: 29345686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How can we reverse bleeding in patients on direct oral anticoagulants?
    Crowther M; Cuker A
    Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols.
    Huisman MV; Fanikos J
    Am J Med; 2016 Nov; 129(11S):S89-S96. PubMed ID: 27569673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Andexanet Alfa Should Be Used to Reverse Factor Xa Inhibitors in the Setting of Life-Threatening Bleeding.
    Brown CS; Gilbert BW
    Ann Emerg Med; 2023 Sep; 82(3):364-365. PubMed ID: 36669921
    [No Abstract]   [Full Text] [Related]  

  • 17. Reversal of direct oral anticoagulants.
    Zhang XY; Desborough MJ; Shapiro S
    Br J Hosp Med (Lond); 2017 Mar; 78(3):165-169. PubMed ID: 28277769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients.
    Highsmith EA; Morton C; Varnado S; Donahue KR; Sulhan S; Lista A
    J Clin Pharmacol; 2021 May; 61(5):598-605. PubMed ID: 33094836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
    Rogers KC; Finks SW
    Am J Med; 2019 Jan; 132(1):38-41. PubMed ID: 30053385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Reversal strategies for non-vitamin K antagonist oral anticoagulants].
    Larsen FU; Hvas AM; Grove EL
    Ugeskr Laeger; 2016 Oct; 178(40):. PubMed ID: 27697119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.